Tango Therapeutics, Inc. Restricted Cash and Cash Equivalents, Noncurrent
Tango Therapeutics, Inc. (TNGX) had Restricted Cash and Cash Equivalents, Noncurrent of $2.14 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Restricted Cash and Cash Equivalent, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2026-08-11
- 2026-06-30: Restricted Cash and Cash Equivalents, Noncurrent $2.14M.
- 2026-03-31: Restricted Cash and Cash Equivalents, Noncurrent $2.14M.
- 2025-12-31: Restricted Cash and Cash Equivalents, Noncurrent $2.57M.
- 2025-09-30: Restricted Cash and Cash Equivalents, Noncurrent $2.57M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2026-06-30 | $2.14M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.14M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $2.57M 10-K · filed 2026-03-05 |
| 2025-09-30 | $2.57M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $2.57M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $2.57M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $2.57M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.57M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $2.57M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $2.57M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $3.42M 10-K · filed 2026-03-05 |
| 2023-09-30 | $3.42M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $3.42M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $3.42M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $3.99M 10-K · filed 2025-02-27 |
| 2021-12-31 | $2.28M 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |